Cécile Delettre

Dr. Cécile Delettre

Université Montpellier Sud de France, Institut of Neurosciences of Montpellier, INSERM U1051, 80 rue Augustin Fliche, Hôpital Saint Eloi, 34090 Montpellier, France

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Nature Genetics
Verified
Journal Article
Closed access
Cécile DelettreCécile Delettre
Cécile Delettre
GLGuy Lenaers
Guy Lenaers
JGJean-Michel Griffoin
Jean-Michel Griffoin
NGNadine Gigarel
Nadine Gigarel
CLCorinne Lorenzo
Corinne Lorenzo
CHChristian P. Hamel
Christian P. Hamel

26 June 2002 in FEBS Letters
Verified
Journal Article
Closed access
AOAurélien Olichon
Aurélien Olichon
LELaurent J Emorine
Laurent J Emorine
EDEric Descoins
Eric Descoins
LPLaetitia Pelloquin
Laetitia Pelloquin
LBLaetitia Brichese
Laetitia Brichese
PBPascale Belenguer
Pascale Belenguer

30 October 2001 in Human Genetics
Verified
Journal Article
Closed access
PDF file
Cécile DelettreCécile Delettre
Cécile Delettre
JGJean-Michel Griffoin
Jean-Michel Griffoin
JKJosseline Kaplan
Josseline Kaplan
HDHélène Dollfus
Hélène Dollfus
BLBirgit Lorenz
Birgit Lorenz
CHChristian P. Hamel
Christian P. Hamel

1 January 2012 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
GLGuy Lenaers
Guy Lenaers
CHChristian P Hamel
Christian P Hamel
Cécile DelettreCécile Delettre
Cécile Delettre
PAPatrizia Amati-Bonneau
Patrizia Amati-Bonneau
VPVincent Procaccio
Vincent Procaccio
DMDan Milea
Dan Milea
DEFINITION OF THE DISEASE: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which transfer the visual information from the photoreceptors to the lateral geniculus in the brain. The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000 in the rest of the world. DOA patients usually suffer of moderate visual loss, associated with central or paracentral visual field deficits and color vision defects. The severity of the disease is highly variable, the visual acuity ranging from normal to legal blindness. The ophthalmic examination discloses on fundoscopy isolated optic disc pallor or atrophy, related to the RGC death. About 20% of DOA patients harbour extraocular multi-systemic features, including neurosensory hearing loss, or less commonly chronic progressive external ophthalmoplegia, myopathy, peripheral neuropathy, multiple sclerosis-like illness, spastic paraplegia or cataracts. Two genes (OPA1, OPA3) encoding inner mitochondrial membrane proteins and three loci (OPA4, OPA5, OPA8) are currently known for DOA. Additional loci and genes (OPA2, OPA6 and OPA7) are responsible for X-linked or recessive optic atrophy. All OPA genes yet identified encode mitochondrial proteins embedded in the inner membrane and ubiquitously expressed, as are the proteins mutated in the Leber Hereditary Optic Neuropathy. OPA1 mutations affect mitochondrial fusion, energy metabolism, control of apoptosis, calcium clearance and maintenance of mitochondrial genome integrity. OPA3 mutations only affect the energy metabolism and the control of apoptosis. Patients are usually diagnosed during their early childhood, because of bilateral, mild, otherwise unexplained visual loss related to optic discs pallor or atrophy, and typically occurring in the context of a family history of DOA. Optical Coherence Tomography further discloses non-specific thinning of retinal nerve fiber layer, but a normal morphology of the photoreceptors layers. Abnormal visual evoked potentials and pattern ERG may also reflect the dysfunction of the RGCs and their axons. Molecular diagnosis is provided by the identification of a mutation in the OPA1 gene (75% of DOA patients) or in the OPA3 gene (1% of patients). Visual loss in DOA may progress during puberty until adulthood, with very slow subsequent chronic progression in most of the cases. On the opposite, in DOA patients with associated extra-ocular features, the visual loss may be more severe over time. To date, there is no preventative or curative treatment in DOA; severely visually impaired patients may benefit from low vision aids. Genetic counseling is commonly offered and patients are advised to avoid alcohol and tobacco consumption, as well as the use of medications that may interfere with mitochondrial metabolism. Gene and pharmacological therapies for DOA are currently under investigation.

25 October 2010 in Genome Research
Verified
Journal Article
Open access
PDF file
GEGhizlane Elachouri
Ghizlane Elachouri
SVSara Vidoni
Sara Vidoni
CZClaudia Zanna
Claudia Zanna
APAlexandre Pattyn
Alexandre Pattyn
HBHASSAN BOUKHADDAOUI
HASSAN BOUKHADDAOUI
GLGuy Lenaers
Guy Lenaers
Eukaryotic cells harbor a small multiploid mitochondrial genome, organized in nucleoids spread within the mitochondrial network. Maintenance and distribution of mitochondrial DNA (mtDNA) are essential for energy metabolism, mitochondrial lineage in primordial germ cells, and to prevent mtDNA instability, which leads to many debilitating human diseases. Mounting evidence suggests that the actors of the mitochondrial network dynamics, among which is the intramitochondrial dynamin OPA1, might be involved in these processes. Here, using siRNAs specific to OPA1 alternate spliced exons, we evidenced that silencing of the OPA1 variants including exon 4b leads to mtDNA depletion, secondary to inhibition of mtDNA replication, and to marked alteration of mtDNA distribution in nucleoid and nucleoid distribution throughout the mitochondrial network. We demonstrate that a small hydrophobic 10-kDa peptide generated by cleavage of the OPA1-exon4b isoform is responsible for this process and show that this peptide is embedded in the inner membrane and colocalizes and coimmunoprecipitates with nucleoid components. We propose a novel synthetic model in which a peptide, including two trans-membrane domains derived from the N terminus of the OPA1-exon4b isoform in vertebrates or from its ortholog in lower eukaryotes, might contribute to nucleoid attachment to the inner mitochondrial membrane and promotes mtDNA replication and distribution. Thus, this study places OPA1 as a direct actor in the maintenance of mitochondrial genome integrity.

1 May 2006 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
AOAurélien Olichon
Aurélien Olichon
EGEmmanuelle Guillou
Emmanuelle Guillou
Cécile DelettreCécile Delettre
Cécile Delettre
TLThomas Landes
Thomas Landes
LALaetitia Arnauné-Pelloquin
Laetitia Arnauné-Pelloquin
PBPascale Belenguer
Pascale Belenguer